Sedation Therapy Market Size, Share, Industry, Forecast and outlook (2024-2031)

Sedation Therapy Market Size

The Sedation Therapy Market is expected to reach at a CAGR of 9.4% during the forecast period (2024-2031).

Sedation therapy is used commonly in minor and a few major procedures, such as suturing a laceration in the emergency room. It is also used in non-painful procedures where patients must remain still for an extended period, such as long diagnostic imaging procedures and the most common MRI procedures.

Market Summary

For more details on this report – Request for Sample

Market Dynamics

The factors expected to drive the global sedation therapy market are the increase in the number of surgical and minimally invasive surgical procedures.

The increase in the number of surgical as well as minimally invasive surgical procedures and advantages of sedation therapy

Minimally invasive surgery accounted for 8.9% of all major cases. It is estimated that over 10 million GI endoscopies are performed in the United States each year. Sedation is also known as monitored anesthesia care, conscious sedation, or twilight sedation, is commonly used for minor surgeries or shorter, less complex procedures when a local anesthetic injection isn't enough but deeper general anesthesia isn't required. Some of these procedures may include biopsies or the use of a scope to examine the throat or colon to detect and treat medical conditions such as cancer.

Intravenous sedation has a rapid onset (up to 2 minutes after the drug, such as midazolam, is injected), and the required dose is usually easily titrated to the patient's needs. The level of sedation achieved while maintaining cooperation and verbal contact is slightly deeper than that of inhalational sedation. Hence, with the increasing number of minimally invasive procedures and the advantages sedation therapies provide are expected to drive the market growth.

Side effects associated with sedation therapy is expected to hamper the market growth

There are different types of sedation, for instance, Palliative sedation is defined as the intentional reduction of the patient's consciousness to a level that adequately relieves refractory and intolerable suffering. It differs from both brief and intermittent sedation, which are used to restore tranquillity before allowing the patient to regain consciousness. Palliative sedation may increase the risk of aspiration, respiratory depression, and worsening agitation caused by delirium. These adverse outcomes are unintended consequences of therapy, not the primary goal of palliative sedation.

The common side effects of procedural sedative therapy are heart rate and blood pressure fluctuations (rare), breathing rate slows down, inhalation of stomach contents into lungs causes a headache (rare), vomiting and nausea, unpleasant recollection of the event. Hence, the side effects of different sedation therapies are expected to hamper the market growth.

COVID-19 Impact Analysis

Sedatives play an important role in COVID-19 patients, acting as induction agents prior to neuromuscular blockade and reducing discomfort during mechanical ventilation. Sedatives facilitate amnesia and cause a blunted sympathetic response during induction, resulting in favorable intubation conditions. Maintenance sedation after intubation improves pulmonary compliance, prevents asynchrony, and facilitates ventilator adaptation; however, additional paralytics are required. Sedation can influence respiratory drive, which is typically very high in COVID-19 patients when they breathe spontaneously. Sedation is important in the COVID-19 pandemic for optimal patient care and the high demand for sedative and analgesic medications. For instance, in March, sedative demand increased by 91%, analgesic demand increased by 79%, and neuromuscular blockers demand increased by 105%.

Hence, the increased demand for sedatives during the COVID-19 treatment is expected to positively impact the sedation therapy market.

Market Segment Analysis

Based on the drug, the Lorazepam segment is expected to dominate the global sedation therapy market

Lorazepam is classified as an intermediate-acting benzodiazepine due to its elimination half-life of 10–20 hours. This classification system, however, is deceptive. Despite having a shorter half-life than diazepam, the actual sedative effect lasts longer due to lower lipid solubility, slowing its redistribution from the brain. Lorazepam undergoes phase II hepatic metabolism via glucuronide conjugation to inactive metabolites rapidly excreted via the kidney, as opposed to phase I hepatic metabolism, which is influenced by competition from the cytochrome P450 enzyme system, which frequently results in inactive metabolites. As a result, lorazepam is less affected by advanced age, hepatic dysfunction, or drug-drug interactions.

 For instance, it has an 83–100% oral bioavailability range, with peak plasma levels occurring 1–2 hours after administration. The onset of action occurs within 60 minutes of oral administration. Adult doses for dental sedation patients can range from 0.5 mg to 4 mg, depending on the patient and procedure. Lorazepam is commonly used as the preferred sedative and anxiolytic in the inpatient setting due to its rapid (1 to 3 minute) onset of action when administered intravenously. It is also one of the few sedative-hypnotics with a low risk of side effects.

Market Geographical Share

North America region is expected to hold the largest market share in the global sedation therapy market

The increasing number of colonoscopies, wound repair, cataract removal, or dental work surgeries is expected to increase the sedation therapy market demand in this region.

For instance, In the United States, around 19 million colonoscopies are performed each year. Midazolam, propofol, diazepam, diphenhydramine, promethazine, meperidine, and fentanyl are currently available as sedative agents for colonoscopy. Propofol and Midazolam are the commonly used sedatives. Hence, with the increasing number of colonoscopies in this region, the demand for sedation therapy is also expected to increase.

The increasing FDA approvals and product launches is also expected to boost the market growth. For instance, on July 2, 2020, Acacia Pharma Group plc's BYFAVOTM (remimazolam) for injection for the induction and maintenance of procedural sedation in adult patients was approved by U.S FDA. BYFAVOTM (remimazolam) for injection, a very rapid onset/offset IV benzodiazepine sedative, is approved for use during invasive medical procedures lasting 30 minutes or less in adults, such as colonoscopy and bronchoscopy.

Market Key Players

With mergers, collaborations, and product launches, the global sedation therapy market is moderately competitive. Some of the key players in the global sedation therapy market are Pfizer, Inc., F. Hoffmann-La Roche Ltd., Bausch Health Companies, Inc., Mylan, N.V., Fresenius Kabi, Aurobindo Pharma, Acacia Pharma, Inc.

Acacia Pharma, Inc

Overview: Acacia Pharma is a biopharmaceutical company in the commercial stage that focuses on developing and commercializing novel products. Acacia Pharma operates its commercial infrastructure in the United States. The company markets its products directly. The company was founded in 2007 and has offices in Cambridge, the United Kingdom, and Indianapolis, Indiana, in the United States.

Product Portfolio: The company manufactures BYFAVO (remimazolam) injection for intravenous administration. Each single-patient-use glass vial contains 20 mg BYFAVO (remimazolam) lyophilized powder for reconstitution, equivalent to 27.2 mg remimazolam besylate.

Key Development: On July 2, 2020, Byfavo (remimazolam) was approved by the Food and Drug Administration (FDA) to induce and maintain procedural sedation in adults undergoing procedures lasting 30 minutes or less.